Michael Sacerdote

Taro: A Beautiful Ugly Duckling

Taro Pharmaceutical Industries (TARO), a maker of generic drugs, has all the hallmarks of a beautifully underfollowed gem: a boring business, a horrible website, coverage by a single analyst, few Seeking Alpha followers, a blizzard of irrelevant SEC filings hiding the useful documents, and zero self-promotion. Want flashy presentations telling you in a few pithy slides exactly how the business functions? Don't expect it from Taro. Nevertheless, despite appreciating dramatically since the prescient articles found here and here by Retail Investor, Taro has a wonderful business with good long-term growth prospects. For serious investors who believe that making money is more important than having conversation-starters available for cocktail parties, Taro is a reasonable and conservative investment with a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details